MindMaze delivers seamless digital assessments and therapeutics over the full continuum of care in over twenty countries. Helping thousands of patients suffering from neurological conditions, the company collaborates with approximately ninety healthcare providers and has a product portfolio that has received three FDA clearances and four CE marks across eight clinical indications.
Backed by over seventy patent families, the company is headquartered in Lausanne (canton of Vaud), at the heart of the Health Valley. MindMaze's innovative digital neurotherapeutics platform combines highly engaging, personalized, protocolized, quantified, gamified digital therapeutic content supported by tailored smart peripherals that target two distinct areas of care : neuro-rehabilitation and neuro-restoration.
The most recent financing in the amount of USD 125 million was provided by AlbaCore Capital Group, one of Europe's leading specialist investors focusing on public and private corporate credit markets. According to an article by Bloomberg, MindMaze is valued at more than USD 1.5 billion after receiving the financing.
Accelerating the commercialization and expansion of MindMaze’s digital neurotherapeutics platform
MindMaze will use the proceeds to accelerate commercialization of, and enhance market access for, its approved and reimbursed neuro-rehabilitation platform, particularly in North America and Europe. It will also expand its neuro-restorative portfolio through further system development and clinical trials in additional indications. These indications include acute stroke, Parkinson disease, Alzheimer disease, traumatic brain injury, multiple sclerosis and aging.
Founded in 2012 as an EPFL spin-off by CEO Dr Tej Tadi and having received the support of Hollywood actor Leonardo DiCaprio, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai. The biotech currently employs 140 people, 80 of them in its Lausanne offices.
